Catalyst Pharmaceuticals Inc (CN2 F) stock market data APIs
€20.719
0.04(0.2%)
as of March 6, 2026
Try our APIs with
free plan!
Catalyst Pharmaceuticals Inc Financial Data Overview
Price chart is built with
Anychart
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States. It offers Firdapse for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); Fycompa, a novel non-competitive selective antagonist at the postsynaptic ionotropic alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid glutamate receptor that is used to treat focal onset seizures, as well as tonic-clonic seizure; and AGAMREE, a corticosteroid for the treatment of duchenne muscular dystrophy. The company has license agreements with BioMarin Pharmaceutical Inc.; and a collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
Prev. Close
20.719
Open
20.7344
High
20.7604
Low
20.5251
52 wk Range
16.15-24
Market Cap
2 574 M
P/E Ratio
14.2828
Shares Outstanding
122 M
Revenue
589 M
Beta
0.707
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Catalyst Pharmaceuticals Inc data using free add-ons & libraries
Get Catalyst Pharmaceuticals Inc Fundamental Data
Catalyst Pharmaceuticals Inc Fundamental data includes:
- Net Revenue: 589 M
- EBITDA: 296 M
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-02-25
- EPS/Forecast: 0.5
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Catalyst Pharmaceuticals Inc News
New
Catalyst Pharmaceuticals to Showcase Real‑World Findings in Duchenne Muscular Dystrophy and Host Vamorolone-Focused Symposium at the 2026 MDA Clinical & Scientific Conference
Catalyst Pharmaceuticals, Inc. CORAL GABLES, Fla., March 06, 2026 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused ...
Why Catalyst Pharmaceuticals (CPRX) Is Up 5.4% After Raising 2026 Revenue Guidance And Highlighting Rare Disease Portfolio
Catalyst Pharmaceuticals recently reported past fourth-quarter 2025 revenue of US$152.61 million and full-year 2025 revenue of US$588.99 million, alongside net income of US$52.7 million for the qua...
Are Investors Undervaluing Catalyst Pharmaceuticals (CPRX) Right Now?
Here at Zacks, we focus on our proven ranking system, which places an emphasis on earnings estimates and estimate revisions, to find winning stocks. But we also understand that investors develop their...
Best Value Stocks to Buy for March 4th
Here are two stocks with buy rank and strong value characteristics for investors to consider today, March 4th: Catalyst Pharmaceuticals CPRX: This commercial-stage biopharmaceutical company, which is...
Get Catalyst Pharmaceuticals Inc fresh news feed via Financial News API
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
